FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012095433> ?p ?o ?g. }

• W2012095433 endingPage "S340" @default.
• W2012095433 startingPage "S340" @default.
• W2012095433 abstract "The graft-versus-leukemia (GVL) effect of donor-lymphocyte infusions (DLI) is well documented in hematologic malignancies, including multiple myeloma (MM). We evaluated the role of DLI in persistent or recurrent MM after allogeneic hematopoietic stem cell transplantation (allo HCT). We identified 23 patients with MM, who received DLI at UT-MD Anderson Cancer Center between 7/1996 -6/2008. Patients had persistent or recurrent disease after allo HCT, and were treated with DLI collected from their original allo HCT donors. Nineteen patients received DLI from matched related donors (MRD) and 4 from matched unrelated donors (MUD). Median age at DLI was 51 years (range: 38-62). A total of 33 DLI doses were administered. Seventeen patients received 1 infusion, 4 patients received 2, and 2 patient received 4 infusions. Median interval between allo HCT and the first DLI was 8.2 months (range: 2.9 to 119.5). Median follow up from the first DLI was 18 months (range 1-126). Twenty-six DLI (78%) were given without preceding cytoreductive chemotherapy. The median DLI dose was 3.5 x 107 CD3+ T cells (range 0.5 to 14.8 x 107). Overall response rate was 30%, with 10 of 33 DLI doses associated with objective clinical responses (3 CR, 5 VGPR, 2 PR). Thirteen (39%) additional DLI were followed by stable disease. Median response duration was 5 months (range 2-10). ORR to DLI in relapsed disease was 10% (2/20), compared to 61% (8/13) for residual disease (p = 0.0048). Grade II-IV acute graft-versus-host disease (GVHD) was seen in 6 (26%) patients, with median onset of 5 weeks from DLI. None of the patients developed chronic GVHD after DLI. Median overall survival from the first DLI was 18.6 months. DLI is associated with objective clinical responses patients with relapsed or persistent MM, with a significantly higher response rate in patients with persistent vs. relapsed disease. The risk of acute GVHD was low. The role of DLI needs to be further explored in prospective clinical trials for patients with relapsed or persistent MM." @default.
• W2012095433 created "2016-06-24" @default.
• W2012095433 creator A5015342719 @default.
• W2012095433 creator A5016928938 @default.
• W2012095433 creator A5026422612 @default.
• W2012095433 creator A5038261300 @default.
• W2012095433 creator A5040975741 @default.
• W2012095433 creator A5048913229 @default.
• W2012095433 creator A5050962913 @default.
• W2012095433 creator A5053904944 @default.
• W2012095433 creator A5065998208 @default.
• W2012095433 creator A5066894053 @default.
• W2012095433 creator A5068834306 @default.
• W2012095433 creator A5070096873 @default.
• W2012095433 creator A5083279961 @default.
• W2012095433 date "2011-02-01" @default.
• W2012095433 modified "2023-10-18" @default.
• W2012095433 title "Donor-Lymphocyte Infusion in Patients With Persistent or Recurrent Multiple Myeloma After Allogeneic Hematopoietic Stem Cell Transplantation" @default.
• W2012095433 doi "https://doi.org/10.1016/j.bbmt.2010.12.559" @default.
• W2012095433 hasPublicationYear "2011" @default.
• W2012095433 type Work @default.
• W2012095433 sameAs 2012095433 @default.
• W2012095433 citedByCount "0" @default.
• W2012095433 crossrefType "journal-article" @default.
• W2012095433 hasAuthorship W2012095433A5015342719 @default.
• W2012095433 hasAuthorship W2012095433A5016928938 @default.
• W2012095433 hasAuthorship W2012095433A5026422612 @default.
• W2012095433 hasAuthorship W2012095433A5038261300 @default.
• W2012095433 hasAuthorship W2012095433A5040975741 @default.
• W2012095433 hasAuthorship W2012095433A5048913229 @default.
• W2012095433 hasAuthorship W2012095433A5050962913 @default.
• W2012095433 hasAuthorship W2012095433A5053904944 @default.
• W2012095433 hasAuthorship W2012095433A5065998208 @default.
• W2012095433 hasAuthorship W2012095433A5066894053 @default.
• W2012095433 hasAuthorship W2012095433A5068834306 @default.
• W2012095433 hasAuthorship W2012095433A5070096873 @default.
• W2012095433 hasAuthorship W2012095433A5083279961 @default.
• W2012095433 hasBestOaLocation W20120954331 @default.
• W2012095433 hasConcept C126322002 @default.
• W2012095433 hasConcept C141071460 @default.
• W2012095433 hasConcept C2776364478 @default.
• W2012095433 hasConcept C2777408962 @default.
• W2012095433 hasConcept C2779695342 @default.
• W2012095433 hasConcept C2911091166 @default.
• W2012095433 hasConcept C71924100 @default.
• W2012095433 hasConcept C90924648 @default.
• W2012095433 hasConceptScore W2012095433C126322002 @default.
• W2012095433 hasConceptScore W2012095433C141071460 @default.
• W2012095433 hasConceptScore W2012095433C2776364478 @default.
• W2012095433 hasConceptScore W2012095433C2777408962 @default.
• W2012095433 hasConceptScore W2012095433C2779695342 @default.
• W2012095433 hasConceptScore W2012095433C2911091166 @default.
• W2012095433 hasConceptScore W2012095433C71924100 @default.
• W2012095433 hasConceptScore W2012095433C90924648 @default.
• W2012095433 hasIssue "2" @default.
• W2012095433 hasLocation W20120954331 @default.
• W2012095433 hasOpenAccess W2012095433 @default.
• W2012095433 hasPrimaryLocation W20120954331 @default.
• W2012095433 hasRelatedWork W2012095433 @default.
• W2012095433 hasRelatedWork W2024036444 @default.
• W2012095433 hasRelatedWork W2052913478 @default.
• W2012095433 hasRelatedWork W2058298326 @default.
• W2012095433 hasRelatedWork W2075400856 @default.
• W2012095433 hasRelatedWork W2108579969 @default.
• W2012095433 hasRelatedWork W2353124159 @default.
• W2012095433 hasRelatedWork W2950846836 @default.
• W2012095433 hasRelatedWork W3031084238 @default.
• W2012095433 hasRelatedWork W3128368052 @default.
• W2012095433 hasVolume "17" @default.
• W2012095433 isParatext "false" @default.
• W2012095433 isRetracted "false" @default.
• W2012095433 magId "2012095433" @default.
• W2012095433 workType "article" @default.